Which has stronger earnings & valuation, VTRS or LQDA?

Liquidia has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.74B 1.26 -$3.51B -$0.36 N/A Liquidia $450.91M 14.10 -$68.92M $1.37 51.86

Is VTRS or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to Viatris' net margin of -2.79%. Liquidia's return on equity of 149.65% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Liquidia 30.74% 149.65% 36.30%

Does the media favor VTRS or LQDA?

In the previous week, Liquidia had 23 more articles in the media than Viatris. MarketBeat recorded 24 mentions for Liquidia and 1 mentions for Viatris. Viatris' average media sentiment score of 0.50 beat Liquidia's score of 0.05 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor JAZZ or LQDA?

In the previous week, Liquidia had 22 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 24 mentions for Liquidia and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.81 beat Liquidia's score of 0.05 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LQDA or NBIX?

In the previous week, Liquidia had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 24 mentions for Liquidia and 15 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.43 beat Liquidia's score of 0.05 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 15 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CORT or LQDA?

Corcept Therapeutics has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corcept Therapeutics $761.41M 17.19 $99.65M $0.42 288.21 Liquidia $450.91M 14.10 -$68.92M $1.37 51.86

Does the media favor CORT or LQDA?

In the previous week, Corcept Therapeutics had 3 more articles in the media than Liquidia. MarketBeat recorded 27 mentions for Corcept Therapeutics and 24 mentions for Liquidia. Corcept Therapeutics' average media sentiment score of 0.78 beat Liquidia's score of 0.05 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELAN or LQDA?

In the previous week, Liquidia had 12 more articles in the media than Elanco Animal Health. MarketBeat recorded 24 mentions for Liquidia and 12 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.32 beat Liquidia's score of 0.05 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Liquidia (LQDA) Competitors

$71.05 -4.28 (-5.68%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$72.11 +1.06 (+1.49%)

As of 08:18 AM Eastern

Compare

LQDA vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Liquidia stock or one of its competitors? Liquidia's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Liquidia compare to Viatris?

Viatris (NASDAQ:VTRS) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

79.9% of Viatris shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Liquidia has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	1.26	-$3.51B	-$0.36	N/A
Liquidia	$450.91M	14.10	-$68.92M	$1.37	51.86

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 8.56%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 38.05%. Given Liquidia's higher probable upside, analysts plainly believe Liquidia is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Liquidia had 23 more articles in the media than Viatris. MarketBeat recorded 24 mentions for Liquidia and 1 mentions for Viatris. Viatris' average media sentiment score of 0.50 beat Liquidia's score of 0.05 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has a net margin of 30.74% compared to Viatris' net margin of -2.79%. Liquidia's return on equity of 149.65% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Liquidia	30.74%	149.65%	36.30%

Summary

Liquidia beats Viatris on 12 of the 17 factors compared between the two stocks.

How does Liquidia compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Liquidia has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.78	-$356.15M	$14.50	17.15
Liquidia	$450.91M	14.10	-$68.92M	$1.37	51.86

Jazz Pharmaceuticals currently has a consensus price target of $272.89, indicating a potential upside of 9.73%. Liquidia has a consensus price target of $98.08, indicating a potential upside of 38.05%. Given Liquidia's higher probable upside, analysts plainly believe Liquidia is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Liquidia had 22 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 24 mentions for Liquidia and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.81 beat Liquidia's score of 0.05 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Liquidia has a net margin of 30.74% compared to Jazz Pharmaceuticals' net margin of 20.45%. Liquidia's return on equity of 149.65% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Liquidia	30.74%	149.65%	36.30%

Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Summary

Liquidia beats Jazz Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Liquidia compare to Neurocrine Biosciences?

Liquidia (NASDAQ:LQDA) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Neurocrine Biosciences has higher revenue and earnings than Liquidia. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$450.91M	14.10	-$68.92M	$1.37	51.86
Neurocrine Biosciences	$2.86B	5.43	$478.60M	$6.82	22.42

In the previous week, Liquidia had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 24 mentions for Liquidia and 15 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.43 beat Liquidia's score of 0.05 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	15 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia currently has a consensus price target of $98.08, indicating a potential upside of 38.05%. Neurocrine Biosciences has a consensus price target of $200.86, indicating a potential upside of 31.34%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Liquidia has a net margin of 30.74% compared to Neurocrine Biosciences' net margin of 20.91%. Liquidia's return on equity of 149.65% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Summary

Liquidia beats Neurocrine Biosciences on 9 of the 16 factors compared between the two stocks.

How does Liquidia compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	17.19	$99.65M	$0.42	288.21
Liquidia	$450.91M	14.10	-$68.92M	$1.37	51.86

In the previous week, Corcept Therapeutics had 3 more articles in the media than Liquidia. MarketBeat recorded 27 mentions for Corcept Therapeutics and 24 mentions for Liquidia. Corcept Therapeutics' average media sentiment score of 0.78 beat Liquidia's score of 0.05 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Corcept Therapeutics currently has a consensus price target of $138.17, suggesting a potential upside of 14.14%. Liquidia has a consensus price target of $98.08, suggesting a potential upside of 38.05%. Given Liquidia's higher probable upside, analysts plainly believe Liquidia is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Liquidia has a net margin of 30.74% compared to Corcept Therapeutics' net margin of 6.52%. Liquidia's return on equity of 149.65% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Liquidia	30.74%	149.65%	36.30%

Summary

Corcept Therapeutics and Liquidia tied by winning 8 of the 16 factors compared between the two stocks.

How does Liquidia compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Liquidia had 12 more articles in the media than Elanco Animal Health. MarketBeat recorded 24 mentions for Liquidia and 12 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.32 beat Liquidia's score of 0.05 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.34	-$232M	-$0.41	N/A
Liquidia	$450.91M	14.10	-$68.92M	$1.37	51.86

Elanco Animal Health presently has a consensus target price of $29.09, suggesting a potential upside of 23.95%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 38.05%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Liquidia has a net margin of 30.74% compared to Elanco Animal Health's net margin of -3.96%. Liquidia's return on equity of 149.65% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Liquidia	30.74%	149.65%	36.30%

Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

Liquidia beats Elanco Animal Health on 10 of the 16 factors compared between the two stocks.

Get Liquidia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LQDA vs. The Competition

Export

Metric	Liquidia	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.74B	$12.62B	$7.35B	$12.83B
Dividend Yield	N/A	2.65%	2.54%	10.69%
P/E Ratio	51.86	779.90	268.95	24.05
Price / Sales	14.10	787.93	578.09	73.21
Price / Cash	N/A	94.24	78.13	53.57
Price / Book	32.59	11.90	13.01	6.15
Net Income	-$68.92M	$2.80B	$3.46B	$347.39M
7 Day Performance	-4.55%	0.60%	0.96%	-0.97%
1 Month Performance	-12.16%	1.52%	3.84%	1.05%
1 Year Performance	160.26%	6.76%	26.46%	19.63%

Liquidia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LQDA Liquidia	4.2454 of 5 stars	$71.05 -5.7%	$98.08 +38.0%	+159.8%	$6.74B	$450.91M	51.86	50	Insider Trade Gap Down
VTRS Viatris	2.0298 of 5 stars	$16.23 flat	$17.50 +7.8%	+51.4%	$18.64B	$14.74B	N/A	30,000
JAZZ Jazz Pharmaceuticals	4.2353 of 5 stars	$248.36 +1.4%	$272.89 +9.9%	+108.9%	$15.90B	$4.27B	17.13	2,890	Positive News
NBIX Neurocrine Biosciences	4.988 of 5 stars	$154.49 +1.2%	$200.86 +30.0%	+14.8%	$15.52B	$2.86B	22.65	2,000	Positive News
CORT Corcept Therapeutics	3.5335 of 5 stars	$117.17 +2.4%	$138.17 +17.9%	+71.9%	$12.37B	$761.41M	278.98	300	Trending News Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LQDA) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liquidia (LQDA) Competitors

LQDA vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Liquidia compare to Viatris?

Summary

How does Liquidia compare to Jazz Pharmaceuticals?

Summary

How does Liquidia compare to Neurocrine Biosciences?

Summary

How does Liquidia compare to Corcept Therapeutics?

Summary

How does Liquidia compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liquidia (LQDA) Competitors

LQDA vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Liquidia compare to Viatris?

Do institutionals and insiders hold more shares of VTRS or LQDA?

Which has stronger earnings & valuation, VTRS or LQDA?

Do analysts prefer VTRS or LQDA?

Which has more risk and volatility, VTRS or LQDA?

Does the media favor VTRS or LQDA?

Is VTRS or LQDA more profitable?

Summary

How does Liquidia compare to Jazz Pharmaceuticals?

Which has better valuation and earnings, JAZZ or LQDA?

Do analysts rate JAZZ or LQDA?

Does the media favor JAZZ or LQDA?

Do institutionals & insiders have more ownership in JAZZ or LQDA?

Is JAZZ or LQDA more profitable?

Which has more volatility & risk, JAZZ or LQDA?

Summary

How does Liquidia compare to Neurocrine Biosciences?

Which has stronger valuation & earnings, LQDA or NBIX?

Does the media refer more to LQDA or NBIX?

Do analysts rate LQDA or NBIX?

Do insiders and institutionals believe in LQDA or NBIX?

Is LQDA or NBIX more profitable?

Which has more volatility & risk, LQDA or NBIX?

Summary

How does Liquidia compare to Corcept Therapeutics?

Do institutionals & insiders have more ownership in CORT or LQDA?

Which has preferable valuation & earnings, CORT or LQDA?

Does the media favor CORT or LQDA?

Which has more risk and volatility, CORT or LQDA?

Do analysts recommend CORT or LQDA?

Is CORT or LQDA more profitable?

Summary

How does Liquidia compare to Elanco Animal Health?

Do insiders & institutionals hold more shares of ELAN or LQDA?

Does the media prefer ELAN or LQDA?

Which has stronger valuation & earnings, ELAN or LQDA?

Do analysts rate ELAN or LQDA?

Is ELAN or LQDA more profitable?

Which has more volatility & risk, ELAN or LQDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools